[
    [
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业专题研究：机构改革组建医药三大部门 监管开启新篇章",
            "features": {
                "keywords": [
                    "医药生物",
                    "机构改革",
                    "三大部门",
                    "监管",
                    "新篇章"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业专题研究：机构改革组建医药三大部门 监管开启新篇章",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "速读社丨恒瑞首个国产IL-17单抗SHR-1314美国开展Ⅱ期临床",
            "features": {
                "keywords": [
                    "恒瑞",
                    "国产",
                    "IL-17单抗",
                    "SHR-1314",
                    "美国",
                    "Ⅱ期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "速读社丨恒瑞首个国产IL-17单抗SHR-1314美国开展Ⅱ期临床",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "持续盈利的独角兽：药明康德、拉卡拉、宁德时代",
            "features": {
                "keywords": [
                    "独角兽",
                    "药明康德",
                    "拉卡拉",
                    "宁德时代",
                    "持续盈利"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "科技",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "持续盈利的独角兽：药明康德、拉卡拉、宁德时代",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]